Atos SE (AXI.F)
| Previous Close | 2.0900 |
| Open | 2.0440 |
| Bid | 2.0880 x 20000 |
| Ask | 2.2980 x 20000 |
| Day's Range | 2.0440 - 2.2060 |
| 52 Week Range | 1.5870 - 14.6950 |
| Volume | |
| Avg. Volume | 4,558 |
| Market Cap | 245.665M |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | May 14, 2021 |
| 1y Target Est | N/A |
- GlobeNewswire
Introducing Eviden's new AI computing portfolio - the ultimate solution to unlock AI’s full potential
BullSequana AI 1200H BullSequana AI 1200H BullSequanaAI 1200H (2) BullSequana AI 1200 Eviden Press Release Introducing Eviden's new AI computing portfolio - the ultimate solution to unlock AI’s full potential Paris, France – May 2, 2024 – Eviden, the Atos Group business leading in advanced computing, today announces its new product line “BullSequana AI.” This full end-to-end offering includes five new AI server ranges optimized for AI workloads and is designed to cater to a diverse range of AI n
- GlobeNewswire
Market update - April 29
Non-binding letter of intent received from the French state to acquire 100% of the Advanced Computing, Mission-Critical Systems and Cybersecurity Products activities of Atos SE’s BDS (Big Data & Security) business Indicative enterprise valuation between €700 million and €1 billionDue diligence phase to start shortly in view of the issuance of a confirmatory non-binding offer by early June 2024 Revision of the parameters of the financial restructuring framework presented on April 9, 2024, to refl
- GlobeNewswire
Atos reports first quarter 2024 performance
Press Release Atos reports first quarter 2024 performance1 Q1 2024 Revenue €2,479m, down -2.6% organically Eviden down -3.9% organically, reflecting continued softness in Americas and the UKTech Foundations down -1.5% organically, reflecting lower scope of work with certain customers in Americas and Central Europe Order entry of €1.6bn for a book-to-bill of 64%, compared with 73% in prior year Eviden book-to-bill at 83%, compared with 79% in prior year, driven by stronger demand in High-Performa
